The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Open accessAbstract
Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with several sGC agonists currently in clinical development. On binding of NO to a prosthetic heme group on sGC, the enzyme catalyzes synthesis of the second messenger cGMP, which produces vasorelaxation and inhibits smooth muscle proliferation, leukocyte recruitment, and platelet aggregation through a number of downstream mechanisms.1,2 Impaired NO and cGMP signaling has been implicated in the pathogenesis of cardiovascular disease, including systemic arterial and pulmonary hypertension (PH), coronary artery disease, peripheral vascular disease (including erectile dysfunction), and atherosclerosis.1,3,–,5 Organic nitrates that target the NO signaling pathway have been used to treat cardiovascular disease for >150 years. More recently, gaseous NO administered by inhalation has been approved for the treatment of persistent PH of the newborn.3,6 These agents nonetheless have several important limitations. Cardiovascular disease is associated with resistance to NO and organic nitrates.7 This may be due to the oxidative stress–induced alteration of the redox state of the prosthetic heme on sGC (from ferrous to ferric) that weakens the binding of heme to the enzyme and renders sGC unresponsive to NO.1,8 Furthermore, the long-term efficacy of organic nitrates is limited by the development of tolerance.9 Nitric oxide may also have numerous cytotoxic effects, mostly attributed to the reactive oxidant peroxynitrite (formed from the diffusion-controlled reaction of NO with superoxide).3,10 Peroxynitrite interacts with proteins and lipids, altering cellular signaling, disrupting mitochondrial function, and damaging DNA, which can eventually culminate in cellular dysfunction and/or death.3 Because the beneficial effects of NO appear to be …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Self-citation2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., & Stewart, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282402 · Cited by 1,842
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Giaid, A., & Saleh, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330403 · Cited by 1,369
Nitric oxide : biology and pathobiology
Ignarro, L. J. (2000) · Cited by 1,306
Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,187
Writing Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Morrell, N. W., Adnot, S., Archer, S. L., Dupuis, J., Lloyd Jones, P., MacLean, M. R., McMurtry, I. F., Stenmark, K. R., Thistlethwaite, P. A., Weissmann, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.018 · Cited by 819
TUDER, R. M., COOL, C. D., GERACI, M. W., WANG, J., ABMAN, S. H., WRIGHT, L., BADESCH, D., & VOELKEL, N. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9804054 · Cited by 806
Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., Schmidt, H. H. H. W., & Stasch, J.-P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2038 · Cited by 749
Self-citationNO-independent regulatory site on soluble guanylate cyclase
Stasch, J.-P., Becker, E. M., Alonso-Alija, C., Apeler, H., Dembowsky, K., Feurer, A., Gerzer, R., Minuth, T., Perzborn, E., Pleiß, U., et al. (2001) · Nature · doi:10.1038/35065611 · Cited by 545
Self-citationLewis, G. D., Shah, R., Shahzad, K., Camuso, J. M., Pappagianopoulos, P. P., Hung, J., Tawakol, A., Gerszten, R. E., Systrom, D. M., Bloch, K. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.716373 · Cited by 515
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Barst, R. J., Gibbs, J. S. R., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Rubin, L. J., Sitbon, O., Tapson, V. F., & Galiè, N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.017 · Cited by 499
Stasch, J.-P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y., H.S., A. K., Meurer, S., Deile, M., Taye, A., Knorr, A., Lapp, H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28371 · Cited by 455
Self-citationExplaining the Phenomenon of Nitrate Tolerance
Münzel, T., Daiber, A., & Mülsch, A. (2005) · Circulation Research · doi:10.1161/01.res.0000184694.03262.6d · Cited by 424
Nitric Oxide and Cyclic GMP in Cell Signaling and Drug Development
Murad, F. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa063904 · Cited by 420
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Tsai, E. J., & Kass, D. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.009 · Cited by 420
YC-1, a novel activator of platelet guanylate cyclase
Ko, F., Wu, C., Kuo, S., Lee, F., & Teng, C. (1994) · Blood · doi:10.1182/blood.v84.12.4226.bloodjournal84124226 · Cited by 402
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Hoeper, M. M., Barberà, J. A., Channick, R. N., Hassoun, P. M., Lang, I. M., Manes, A., Martinez, F. J., Naeije, R., Olschewski, H., Pepke-Zaba, J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.008 · Cited by 399
Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1587oc · Cited by 371
Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.
Friebe, A., Schultz, G., & Koesling, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01078.x · Cited by 352
Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure
Guazzi, M., Samaja, M., Arena, R., Vicenzi, M., & Guazzi, M. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.078 · Cited by 323
Stasch, J., Schmidt, P., Alonso‐Alija, C., Apeler, H., Dembowsky, K., Haerter, M., Heil, M., Minuth, T., Perzborn, E., Pleiss, U., et al. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704778 · Cited by 313
Self-citationDefective l -Arginine–Nitric Oxide Pathway in Offspring of Essential Hypertensive Patients
Taddei, S., Virdis, A., Mattei, P., Ghiadoni, L., Sudano, I., & Salvetti, A. (1996) · Circulation · doi:10.1161/01.cir.94.6.1298 · Cited by 311
Sitbon, O., Humbert, M., Jagot, J., Taravella, O., Fartoukh, M., Parent, F., Herve, P., & Simonneau, G. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12020265 · Cited by 301
Eddahibi, S., Guignabert, C., Barlier-Mur, A.-M., Dewachter, L., Fadel, E., Dartevelle, P., Humbert, M., Simonneau, G., Hanoun, N., Saurini, F., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.591321 · Cited by 297
Role of oxidative stress and nitric oxide in atherothrombosis
Lubos, E. (2008) · Frontiers in Bioscience · doi:10.2741/3084 · Cited by 285
Discovery of the nitric oxide signaling pathway and targets for drug development
Bryan, N. (2009) · Frontiers in Bioscience · doi:10.2741/3228 · Cited by 254
Grimminger, F., Weimann, G., Frey, R., Voswinckel, R., Thamm, M., Bölkow, D., Weissmann, N., Mück, W., Unger, S., Wensing, G., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00039808 · Cited by 249
Ghofrani, H. A., Hoeper, M. M., Halank, M., Meyer, F. J., Staehler, G., Behr, J., Ewert, R., Weimann, G., & Grimminger, F. (2010) · European Respiratory Journal · doi:10.1183/09031936.00182909 · Cited by 240
Nitrosative stress and pharmacological modulation of heart failure
Pacher, P., Schulz, R., Liaudet, L., & Szabó, C. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.04.003 · Cited by 237
Self-citationExpression and function of soluble guanylate cyclase in pulmonary arterial hypertension
Schermuly, R. T., Stasch, J.-P., Pullamsetti, S. S., Middendorff, R., Müller, D., Schlüter, K.-D., Dingendorf, A., Hackemack, S., Kolosionek, E., Kaulen, C., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00114407 · Cited by 237
Self-citationAhluwalia, A., Foster, P., Scotland, R. S., McLean, P. G., Mathur, A., Perretti, M., Moncada, S., & Hobbs, A. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304264101 · Cited by 229
Dumitrascu, R., Weissmann, N., Ghofrani, H. A., Dony, E., Beuerlein, K., Schmidt, H., Stasch, J.-P., Gnoth, M. J., Seeger, W., Grimminger, F., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.581405 · Cited by 224
Self-citationMülsch, A., Bauersachs, J., Schäfer, A., Stasch, J., Kast, R., & Busse, R. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700982 · Cited by 222
Self-citationNO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators
Stasch, J.-P., & Hobbs, A. J. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-68964-5_13 · Cited by 205
Self-citationMechanism of YC-1-Induced Activation of Soluble Guanylyl Cyclase
Friebe, A., & Koesling, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.123 · Cited by 201
Recent Advances in Understanding Endothelial Dysfunction in Atherosclerosis
Yang, Z., & Ming, X.-F. (2006) · Clinical Medicine & Research · doi:10.3121/cmr.4.1.53 · Cited by 189
Mittendorf, J., Weigand, S., Alonso‐Alija, C., Bischoff, E., Feurer, A., Gerisch, M., Kern, A., Knorr, A., Lang, D., Muenter, K., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900014 · Cited by 186
Self-citationPullamsetti, S., Kiss, L., Ghofrani, H. A., Voswinckel, R., Haredza, P., Klepetko, W., Aigner, C., Fink, L., Muyal, J. P., Weissmann, N., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3223fje · Cited by 176
Galle, J., Zabel, U., Hübner, U., Hatzelmann, A., Wagner, B., Wanner, C., & Schmidt, H. H. H. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702495 · Cited by 173
Burley, D. S., Ferdinandy, P., & Baxter, G. F. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707409 · Cited by 167
YC-1 Potentiates Nitric Oxide- and Carbon Monoxide-Induced Cyclic GMP Effects in Human Platelets
Friebe, A., Müllershausen, F., Smolenski, A., Walter, U., Schultz, G., & Koesling, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.6.962 · Cited by 167
Phosphodiesterase regulation of nitric oxide signaling
KASS, D., Takimoto, E., Nagayama, T., & Champion, H. C. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.02.031 · Cited by 162
Inhaled NO as a therapeutic agent
BLOCH, K., ICHINOSE, F., ROBERTSJR, J., & ZAPOL, W. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.04.014 · Cited by 159
NO- and Haem-Independent Soluble Guanylate Cyclase Activators
Schmidt, H. H. H. W., Schmidt, P. M., & Stasch, J.-P. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-68964-5_14 · Cited by 158
Self-citationErdmann, E., Semigran, M. J., Nieminen, M. S., Gheorghiade, M., Agrawal, R., Mitrović, V. L., & Mebazaa, A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs196 · Cited by 155
Dunkern, T. R., Feurstein, D., Rossi, G. A., Sabatini, F., & Hatzelmann, A. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.036 · Cited by 150
NO-Independent stimulators of soluble guanylate cyclase
Straub, A., Stasch, J., Alonso‐Alija, C., Benet‐Buchholz, J., Ducke, B., Feurer, A., & Fürstner, C. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00073-7 · Cited by 149
Self-citationLapp, H., Mitrovic, V., Franz, N., Heuer, H., Buerke, M., Wolfertz, J., Mueck, W., Unger, S., Wensing, G., & Frey, R. (2009) · Circulation · doi:10.1161/circulationaha.108.800292 · Cited by 148
Stasch, J., Alonso‐Alija, C., Apeler, H., Dembowsky, K., Feurer, A., Minuth, T., Perzborn, E., Schramm, M., & Straub, A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704484 · Cited by 132
Self-citationHuman recombinant soluble guanylyl cyclase: Expression, purification, and regulation
Lee, Y.-C., Martin, E., & Murad, F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190333697 · Cited by 129
Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension
Leuchte, H. H., Schwaiblmair, M., Baumgartner, R., Neurohr, C., Kolbe, T., & Behr, J. (2004) · CHEST Journal · doi:10.1378/chest.125.2.580 · Cited by 129
Behling, A., Rohde, L. E. P., Colombo, F., Goldraich, L. A., Stein, R., & Clausell, N. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.11.006 · Cited by 127
Zakrzewicz, D., & Eickelberg, O. (2009) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-9-5 · Cited by 126
Schlaich, M. P., Parnell, M. M., Ahlers, B. A., Finch, S., Marshall, T., Zhang, W., & Kaye, D. M. (2004) · Circulation · doi:10.1161/01.cir.0000149748.79945.52 · Cited by 124
Stasch, J., Dembowsky, K., Perzborn, E., Stahl, E., & Schramm, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704483 · Cited by 120
Self-citationImpaired tissue responsiveness to organic nitrates and nitric oxide: A new therapeutic frontier?
Chirkov, Y. Y., & Horowitz, J. D. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.012 · Cited by 117
Frey, R., Mück, W. M., Unger, S., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008319793 · Cited by 114
Evgenov, O. V., Ichinose, F., Evgenov, N. V., Gnoth, M. J., Falkowski, G. E., Chang, Y., Bloch, K. D., & Zapol, W. M. (2004) · Circulation · doi:10.1161/01.cir.0000144469.01521.8a · Cited by 106
Self-citationBoerrigter, G., Costello‐Boerrigter, L. C., Cataliotti, A., Tsuruda, T., Harty, G. J., Lapp, H., Stasch, J., & Burnett, J. C. J. (2003) · Circulation · doi:10.1161/01.cir.0000055737.15443.f8 · Cited by 103
Self-citationMelichar, V. O., Behr‐Roussel, D., Zabel, U., UTTENTHAL, L. O., Rodrigo, J., Rupin, A., Verbeuren, T. J., Kumar, A. H. S., & Schmidt, H. H. H. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405509101 · Cited by 103
Sharkovska, Y., Kalk, P., Lawrenz, B., Godes, M., Hoffmann, L. S., Wellkisch, K., Geschka, S., Relle, K., Hocher, B., & Stasch, J. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833b558c · Cited by 101
Self-citationTargeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure
Boerrigter, G., Costello‐Boerrigter, L. C., Cataliotti, A., Lapp, H., Stasch, J., & Burnett, J. C. J. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.083832 · Cited by 101
Self-citationSchindler, U., Strobel, H., Schönafinger, K., Linz, W., Löhn, M., Martorana, P. A., Rütten, H., Schindler, P. W., Busch, A. E., Sohn, M., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.018747 · Cited by 100
Martin, F., Baskaran, P., Ma, X., Dunten, P., Schäfer, M., Stasch, J., Beuve, A. V., & van den Akker, F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.111559 · Cited by 100
Self-citationSelwood, D. L., Brummell, D. G., Budworth, J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001034k · Cited by 98
Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury
Korkmaz, S., Radovits, T., Barnucz, E., Hirschberg, K., Neugebauer, P., Loganathan, S., Veres, G., Páli, S., Seidel, B., Zöllner, S. K., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.870774 · Cited by 95
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase
Schmidt, P. M., Schramm, M., Schröder, H., & Stasch, J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01674-1 · Cited by 90
Self-citationCanalli, A. A., Franco‐Penteado, C. F., Saad, S. T. O., Conran, N., & Costa, F. F. (2008) · Haematologica · doi:10.3324/haematol.12119 · Cited by 86
Gladwin, M. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29807 · Cited by 85
Teng, C., Wu, C., Ko, F., Lee, F., & Kuo, S. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00911-9 · Cited by 85
cGMP: Generators, Effectors and Therapeutic Implications
Schmidt, H. H. H. W., Hofmann, F. B., & Stasch, J. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68964-5 · Cited by 83
Self-citationMasuyama, H., Tsuruda, T., Sekita, Y., Hatakeyama, K., Imamura, T., Kato, J., Asada, Y., Stasch, J., & Kitamura, K. (2009) · Hypertension Research · doi:10.1038/hr.2009.64 · Cited by 82
Self-citationInhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation
Evgenov, O. V., Kohane, D. S., Bloch, K. D., Stasch, J., Volpato, G. P., Bellas, E., Evgenov, N. V., Buys, E. S., Gnoth, M. J., Graveline, A. R., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1121oc · Cited by 77
Self-citationMasuyama, H., Tsuruda, T., Kato, J., Imamura, T., Asada, Y., Stasch, J., Kitamura, K., & Eto, T. (2006) · Hypertension · doi:10.1161/01.hyp.0000241087.12492.47 · Cited by 76
Self-citationPankey, E. A., Bhartiya, M., Badejo, A. M., Haider, U., Stasch, J., Murthy, S. N., Nossaman, B. D., & Kadowitz, P. J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00953.2010 · Cited by 71
Self-citationRusswurm, M., Mergia, E., Müllershausen, F., & Koesling, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110570200 · Cited by 71
Müllershausen, F., Russwurm, M., Friebe, A., & Koesling, D. (2004) · Circulation · doi:10.1161/01.cir.0000126286.47618.bd · Cited by 69
Deruelle, P., Grover, T. R., & Abman, S. H. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00119.2005 · Cited by 67
Hoffmann, L., Schmidt, P., Keim, Y., Schaefer, S., Schmidt, H. H. H. W., & Stasch, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00263.x · Cited by 66
Self-citationProbing the presence of the ligand‐binding haem in cellular nitric oxide receptors
Roy, B., Mo, E., Vernon, J., & Garthwaite, J. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707687 · Cited by 62
A-350619: A novel activator of soluble guanylyl cyclase
Miller, L. N., Nakane, M., Hsieh, G. C., et al. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02361-5 · Cited by 62
Rothermund, L., Friebe, A., Paul, M., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703320 · Cited by 55
Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272
Hobbs, A. J., & Moncada, S. (2003) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00046-6 · Cited by 54
Zanfolin, M., Faro, R., de Araújo, E. G., Guaraldo, A. M. A., Antunes, E., & Nucci, G. D. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000210071.54828.9b · Cited by 53
Nagayama, T., Zhang, M., Hsu, S., Takimoto, E., & Kass, D. A. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137422 · Cited by 51
Tulis, D. A., Masters, K. S. B., Lipke, E. A., Schiesser, R. L., Evans, A. J., Peyton, K. J., Durante, W., West, J. L., & Schafer, A. I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6552 · Cited by 51
Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study
Frey, R., Mück, W. M., Kirschbaum, N., Krätzschmar, J., Weimann, G., & Wensing, G. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010378119 · Cited by 45
YC-1, a Benzyl Indazole Derivative, Stimulates Vascular cGMP and Inhibits Neointima Formation
Tulis, D. A., Durante, W., Peyton, K. J., Chapman, G. B., Evans, A. J., & Schafer, A. I. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3942 · Cited by 45
Krieg, T., Liu, Y., Rutz, T., Methner, C., Yang, X. M., Dost, T., Felix, S. B., Stasch, J. P., Cohen, M. V., & Downey, J. M. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp143 · Cited by 45
Self-citationBAY 41-2272 Activates Two Isoforms of Nitric Oxide- Sensitive Guanylyl Cyclase
Koglin, M., Stasch, J., & Behrends, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6764 · Cited by 42
Self-citationSchäfer, A., Fraccarollo, D., Werner, L., & Bauersachs, J. K. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.06.008 · Cited by 39
Role of guanylate cyclase modulators in decompensated heart failure
Mitrović, V. L., Hernandez, A. F., Meyer, M., & Gheorghiade, M. (2009) · Heart Failure Reviews · doi:10.1007/s10741-009-9149-7 · Cited by 39
Cáu, S. B. D. A., Dias-Junior, C. A., Montenegro, M. F., Nucci, G. D., Antunes, E., & Tanus-Santos, J. E. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.030 · Cited by 38
Lee, J. E., Patel, K., Almodóvar, S., et al. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00767.2010 · Cited by 37
Effects of the sGC Stimulator BAY 41-2272 Are Not Mediated by Phosphodiesterase 5 Inhibition
Bischoff, E., & Stasch, J. (2004) · Circulation · doi:10.1161/01.cir.0000142209.28862.12 · Cited by 32
Self-citationHobbs, A. J. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.6.735 · Cited by 32
Kasseckert, S. A., Schäfer, C., Kluger, A., Gligorievski, D., Tillmann, J., Schlüter, K., Noll, T., Sauer, H., Piper, H. M., & Abdallah, Y. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp065 · Cited by 31
Radovits, T., Korkmaz, S., Miesel-Gröschel, C., Seidel, B., Stasch, J., Merkely, B. P., Karck, M., & Szabo, G. B. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.05.025 · Cited by 31
Self-citationWu, C., Chang, W., Chang, G.-Y., Kuo, S., & Teng, C. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.94.252 · Cited by 30
Benz, K., Orth, S. R., Simonaviciene, A., Linz, W., Schindler, U., Rütten, H., & Amann, K. (2007) · Kidney & Blood Pressure Research · doi:10.1159/000104091 · Cited by 29
Egemnazarov, B., Sydykov, A. S., SCHERMULY, R. T., Weißmann, N., Stasch, J., Шогаибович, С. А., Seeger, W., Grimminger, F., & Ghofrani, H. A. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90377.2008 · Cited by 23
Self-citationWang, J.-P., Chang, L.-C., Huang, L.-J., & Kuo, S.-C. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00725-0 · Cited by 23
Kalsi, J., Ralph, D. J., Madge, D. J., Kell, P. D., & Cellek, S. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901224 · Cited by 22
Freitas, C. F., Morganti, R. P., Annichino‐Bizzacchi, J. M., Nucci, G. D., & Antunes, E. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04524.x · Cited by 22
Oberwittler, H., Hirschfeld‐Warneken, A., Wesch, R., Willerich, H., Teichert, L., Lehr, K., Ding, R., Haefeli, W. E., & Mikus, G. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006294540 · Cited by 20
Tamargo, J. L., Duarte, J., Caballero, R., & Delpón, E. (2010) · PubMed · Cited by 18
Claudino, M. A., Silva, F. H., Mónica, F. Z., Rojas-Moscoso, J. A., Nucci, G. D., & Antunes, E. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09776.x · Cited by 17
Jones, E. S., Kemp‐Harper, B. K., Stasch, J., et al. (2009) · BMC Pharmacology · doi:10.1186/1471-2210-9-s1-p29 · Cited by 17
Self-citationAcrylamide Analog as a Novel Nitric Oxide-Independent Soluble Guanylyl Cyclase Activator
Nakane, M., Kolasa, T., Chang, R., Miller, L. N., Moreland, R. B., & Brioni, J. D. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fpj06017x · Cited by 16
Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor
Sovershaev, M. A., Egorina, E. M., Hansen, J., Østerud, B., Pacher, P., Stasch, J., & Evgenov, O. V. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.192690 · Cited by 16
Self-citationLessons from oncology to understand and treat pulmonary hypertension
Adnot, S., & Eddahibi, S. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01618.x · Cited by 15
Pulmonary hypertension in chronic heart failure
Bonderman, D., Martischnig, A. M., Moertl, D., & Lang, I. M. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01950.x · Cited by 15
Hobbs, A. J., & Stasch, J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-373866-0.00009-5 · Cited by 13
Self-citationEmerging drugs for pulmonary hypertension
Girgis, R. E. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903551271 · Cited by 12
Role of the sGC activator ataciguat sodium (HMR1766) in cardiovascular disease
van Eickels, M., Waßmann, S., Schäfer, A., Bauersachs, J. K., Strobel, H., & Rütten, H. (2007) · BMC Pharmacology · doi:10.1186/1471-2210-7-s1-s4 · Cited by 8
Tsai, I., Lin, C., Huang, C., Lin, Y., Yang, C.-M., Lin, Y., & Liao, C. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.05.010 · Cited by 7
Cardiovascular effects of the soluble guanylyl cyclase activator BAY 58–2667 in anesthetized dogs
Hoffmann, M., & Thuß, U. (2007) · BMC Pharmacology · doi:10.1186/1471-2210-7-s1-p28 · Cited by 4
Cited by
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Vericiguat in patients with heart failure and reduced ejection fraction
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915928 · Cited by 1,358
Riociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Pulmonary Hypertension Due to Left Heart Diseases
Vachiéry, J.-L., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, J. S. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.033 · Cited by 636
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Metadata
- Authors
- Stasch, J.-P., Pacher, P., & Evgenov, O. V.
- Venue
- Circulation
- Published
- 2011-05-24
- Volume
- 123
- Issue
- 20
- Pages
- 2263-2273
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2090159456
- Cited by
- 601
- References
- 126
- FWCI
- 29.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.